Anti-Csf1R Monoclonal Antibody SNDX-6352
Anti-Csf1R Monoclonal Antibody SNDX-6352 Uses, Dosage, Side Effects, Food Interaction and all others data.
Anti-Csf1R Monoclonal Antibody SNDX-6352 is under investigation in clinical trial NCT04301778 (Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-embolization for Patients With Intrahepatic Cholangiocarcinoma).
| Trade Name | Anti-Csf1R Monoclonal Antibody SNDX-6352 |
| Generic | Axatilimab |
| Axatilimab Other Names | anti-Csf1R monoclonal antibody SNDX-6352, Axatilimab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
How Anti-Csf1R Monoclonal Antibody SNDX-6352 works
Anti-Csf1R Monoclonal Antibody SNDX-6352 is a high affinity antibody targeting the colony stimulating factor 1 receptors (CSF-1R). Its actions at CSF-1R allows for the regulation of the expansion and infiltration of donor-derived macrophages that mediate chronic graft versus host disease.
Innovators Monograph
You find simplified version here Anti-Csf1R Monoclonal Antibody SNDX-6352
